Trial reportArchives of dermatological research2024
Comparison of the efficacy of combination treatment of microneedling and topical Bleomycin with cryotherapy for the management of hand and foot refractory warts.
Trial report in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Several studies have looked into the effectiveness of bleomycin treatment for warts using various injection methods, such as intralesional injection, multiple puncture technique, jet injection, and moonlet needle prick method, in various concentrations and doses. However, injection methods have been linked to acute pain and bleeding. The purpose of this study is to examine the efficacy of microneedling combination with topical bleomycin and cryotherapy in the treatment of resistant warts on the hands and feet. This randomized clinical trial, conducted at Sina Hospital in Tabriz, involved 90 patients with treatment-resistant warts on their hands and feet. Treatment measures were repeated every two weeks in treatment-resistant patients who did not react to four cryotherapy sessions or whose lesions remained stable for six months. Each wart lesion was randomly assigned to one of two treatment groups: topical bleomycin with microneedling or cryotherapy. The effectiveness of the treatment in weeks 2, 4, 6, and 8 with PGA and PaGA, the amount of clearance, and side effects were evaluated in each session and the 8th week. Pain during therapy was assessed using a visual analog scale (VAS) ranging from 0 to 10. The patients' mean age was 33.65 ± 12.24 years, with 63.3% being female. A total of 186 resistant wart lesions were treated, with 98 (52.7%) situated in the palmar region and 88 (47.3%) in the plantar region. In palm lesions, the bleomycin micro-needling group had a considerably greater clearance rate than the cryotherapy group (86.4% vs. 61.9%; p = 0.001). In foot lesions, the bleomycin microneedling group had a greater clearance rate than the cryotherapy group, although there was no statistically significant difference (69.6% vs. 54.2%; p = 0.209). In the eighth week following the intervention, the number of lesions and the diameter of warts on the palms and feet decreased significantly in the bleomycin microneedling group when compared to the cryotherapy group. Bleomycin microneedling had no adverse effects; however, in patients undergoing cryotherapy, local pain, blisters, and scars were noted. Bleomycin microneedling has a higher therapeutic efficiency than cryotherapy for treating refractory hand and foot warts, and it removes lesions more effectively. In addition, this therapeutic method is safer and has fewer side effects than cryotherapy.
Indexed as
Identifiers
39704831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.